An FTC review of the Sanofi/Translate merger has a new deadline after agency calls for more time
The old saying goes, “good things come to those who wait”— but in Sanofi’s case, more waiting on US regulators to approve its Translate Bio buyout is likely far from a good thing.
On Aug. 27, Sanofi and Translate refiled their premerger notification with the FTC after the agency indicated in “informal discussions” that it needed more time to review the biotech and pharma giant’s tie-up, Translate said in an SEC filing.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.